Search

The Coronavirus Disease 2019 (COVID-19) caused by the new Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2) human coronavirus in Wuhan province of China triggered a worldwide respiratory outbreak. To date, antimalarial hydroxychloroquine and some antivirals such as remdesivir, lopinavir/ritonavir, favipiravir was found to be a treatment option for SARS-CoV-2. In addition to supportive therapy such as oxygen supply and extra corporeal membrane oxygenation in critically ill patients, various treatments such as cytokine inhibitors, stem cell therapy, and immune-convalescent plasma (CP) are being explored. Administration of antibodies against a particular agent to a susceptible person for protection or treatment against an infectious disease associated with this agent is called passive antibody therapy, namely, CP therapy. In the worldwilde, so many recovering patient can be candidates of COVID-19 CP donors after detailed clinical and laboratory evaluations. SARS-CoV-2-specific IgG antibodies passively transmitted by transfused plasma can neutralize viral particles and activate the complement system. Thus, viral elimination may be possible. However, it is also important to know that plasma transfusions may be associated with transfusion reactions such as allergic reactions, transfusion-associated acute lung injury and circulating overload. It is essential to establish protocols for the collection, preparation and implementation of the CP in response to the current pandemic. However, the results of the studies on this issue are controversial. In this review, it is aimed to summarize the recommendations in the current literature for the treatment of CP as a therapeutic option for COVID-19. [ABSTRACT FROM AUTHOR]